A pan-specific antiserum produced by a novel immunization strategy shows a high spectrum of neutralization against neurotoxic snake venoms

Kavi Ratanabanangkoon1,2✉, Kae Yi Tan3, Kritsada Pruksaphon4, Chaiya Klinpayom5, José María Gutiérrez6, Naeem H. Quraishi7 & Choo Hock Tan8✉

Snakebite envenomation is a neglected tropical disease of high mortality and morbidity largely due to insufficient supply of effective and affordable antivenoms. Snake antivenoms are mostly effective against the venoms used in their production. It is thus crucial that effective and affordable antivenom(s) with wide para-specificity, capable of neutralizing the venoms of a large number of snakes, be produced. Here we studied the pan-specific antiserum prepared previously by a novel immunization strategy involving the exposure of horses to a ‘diverse toxin repertoire’ consisting of 12 neurotoxic Asian snake toxin fractions/venoms from six species. This antiserum was previously shown to exhibit wide para-specificity by neutralizing 11 homologous and 16 heterologous venoms from Asia and Africa. We now show that the antiserum can neutralize 9 out of 10 additional neurotoxic venoms. Altogether, 36 snake venoms belonging to 10 genera from 4 continents were neutralized by the antiserum. Toxin profiles previously generated using proteomic techniques of these 36 venoms identified α-neurotoxins, β-neurotoxins, and cytotoxins as predominant toxins presumably neutralized by the antiserum. The bases for the wide para-specificity of the antiserum are discussed. These findings indicate that it is feasible to generate antivenoms of wide para-specificity against elapid neurotoxic venoms from different regions in the world and raises the possibility of a universal neurotoxic antivenom. This should reduce the mortality resulting from neurotoxic snakebite envenomation.

Snakebite envenomation is a neglected tropical disease of high mortality and morbidity in the world, particularly in sub-Saharan Africa, Asia and Latin America, with about 2.7 million envenomings and between 81,000 and 138,000 deaths a year.1–3 This is primarily due to a limited production and inadequate supply of effective and affordable antivenoms. Snake antivenoms are specific against venoms used as immunogens, and those of closely related species; cross reaction or cross neutralization with venoms from other phylogenetically distant species is not often observed.4–8 Thus, antivenoms are mainly used to treat envenomations by snakes that are native to a particular country or region, and generally cannot be used on a larger geographical scale, in contrast to immunoglobulins for rabies or tetanus toxin. Consequently, antivenoms are produced in relatively small volumes for local or regional use and, as a result, the cost of the product is high.

1Department of Microbiology, Faculty of Science, Mahidol University, Rama 6 Road, Bangkok, 10400, Thailand. 2Laboratory of Immunology, Chulabhorn Research Institute, Bangkok, 10210, Thailand. 3Department of Molecular Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia. 4Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. 5Veterinary Hospital, The Veterinary and Remount Department, The Royal Thai Army, Nakorn Pathom, 73000, Thailand. 6Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica. 7Anti Snake Venom/Anti Rabies Serology Laboratory, People’s University of Medical and Health Sciences for Women, Nawabshah, Pakistan. 8Department of Pharmacology, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia. ✉e-mail: kavi.rtn@mahidol.ac.th; tanch@um.edu.my
In the present study, we demonstrated that this pan-specific antiserum also neutralized nine additional neurotoxic venoms from snakes inhabiting wide geographic areas. Such antivenoms could save lives of victims where no locally made antivenom is available. Better still, if ‘universal’ antivenoms, like the equine anti-rabies or anti-tetanus antitoxin, could be produced in large volumes, the cost would be lower as a result of economies of scale. These lifesaving products would then be more affordable to poor people and health authorities in developing countries where the highest incidences of snakebites occur. Furthermore, pan-specific antivenoms with wide para-specificity. These toxin fractions contained all the toxic components of the venoms, mostly presynaptic and postsynaptic neurotoxins and cytotoxins, but were devoid of the high molecular mass, highly immunogenic non-toxic proteins. This antiserum neutralizes over two dozen homologous /heterologous elapid venoms of snakes inhabiting Asia and Africa. The antiserum was prepared using a ‘diverse toxin repertoire’ of the neurotoxic snakes as immunogen. The term ‘diverse toxin repertoire’ represents a mixture of toxin fractions of a large number of different but toxicologically related snakes. The immunization strategy is aimed at exposing the animals’ immune system to a large number of epitopes of the lethal toxins. This should result in the production of antibodies with a variety of paratopes against the diverse toxin epitopes, and consequently, exhibit wide para-specificity. These toxin fractions contained all the toxic components of the venoms, mostly presynaptic and postsynaptic neurotoxins and cytotoxins, but were devoid of the high molecular mass, highly immunogenic non-toxic proteins. This antiserum neutralizes over two dozen homologous /heterologous elapid venoms of snakes inhabiting Asia and Africa.

In the present study, we demonstrated that this pan-specific antiserum also neutralized nine additional neurotoxic venoms of elapids from Central America, Africa, and Australia, including sea snakes and sea kraits. Altogether, 36 neurotoxic venoms from 4 continents have been shown to be neutralized by the antiserum. The

| Elapid snakes          | Challenge dose (number of LD50s) | i.v. LD50 (µg/g)a | ED50 (µl)b | ER50 (mg/ml)c | Potency, P (mg/ml)d |
|------------------------|---------------------------------|-------------------|------------|--------------|-------------------|
| 1 Laticauda colubrina  | 1.5                             | 0.15              | 170.16     | 0.030        | 0.010             |
| (Bali, Indonesia)      |                                 | (0.14-0.17)       | (153.72-188.37) | (0.028-0.034) |                   |
| (Venom Supplies, Australia) |                      |                   |            |              |                   |
| 2 Hydrophiis schistosus| 2.5                             | 0.07              | 201.49     | 0.019        | 0.012             |
| (Penang, Malaysia)   |                                 | (0.05-0.09)       | (193.30-210.03) | (0.014-0.025) |                   |
| (Wild caught specimens)|                               |                   |            |              |                   |
| 3 Notechis scutatus    | 2.5                             | 0.09              | 146.90     | 0.034        | 0.020             |
| (southern Australia)  |                                 | (0.06-0.14)       | (129.05-167.21) | (0.022-0.052) |                   |
| (Venom Supplies, Australia) |                      |                   |            |              |                   |
| 4 Oxyuranus scutellatus| 2.5                             | 0.03              | 69.78      | 0.027        | 0.016             |
| (Australia)           |                                 | (0.02-0.04)       | (52.49-92.76) | (0.018-0.036) |                   |
| (Venom Supplies, Australia) |                      |                   |            |              |                   |
| 5 Pseudechis australis | 1.5                             | 0.31              | 76.32      | 0.152        | 0.051             |
| (Australia)           |                                 | (0.24-0.40)       | (68.22-85.37) | (0.118-0.197) |                   |
| (Venom Supplies, Australia) |                      |                   |            |              |                   |
| 6 Naja senegalensis    | 2.5                             | 0.39              | 78.95      | 0.309        | 0.185             |
| (Mali, West Africa)   |                                 | (0.25-0.61)       | (63.80-97.69) | (0.198-0.483) |                   |
| (Latoxan, France)     |                               |                   |            |              |                   |
| 7 Dendroaspis viridis  | 1.5                             | 0.15              | 139.56     | 0.039        | 0.013             |
| (Ghana, West Africa)  |                                 | (0.13-0.17)       | (104.98-185.53) | (0.034-0.044) |                   |
| (Latoxan, France)     |                               |                   |            |              |                   |
| 8 Dendroaspis polylepis| 2.5                             | 0.28              | 152.63     | 0.105        | 0.063             |
| (Kenya, East Africa)  |                                 | (0.16-0.51)       | (136.44-170.74) | (0.060-0.192) |                   |
| (Latoxan, France)     |                               |                   |            |              |                   |
| 9 Dendroaspis angusticeps | 1.5                         | 1.53              | >200       | Not effective | —                 |
| (Tanzania, East Africa) |                             | (1.36-1.71)      |            |              |                   |
| (Latoxan, France)     |                               |                   |            |              |                   |
| 10 Micrurus nigrocinctus| 2.5                            | 0.51              | 139.56     | 0.201        | 0.121             |
| (Costa Rica)          |                                 | (0.45-0.58)       | (104.98-185.53) | (0.177-0.229) |                   |
| (Wild caught specimens)|                           |                   |            |              |                   |

Table 1. Lethality of 10 neurotoxic venoms from four different continents and the neutralizing efficacy of horse pan-specific antiserum. LD50: Median lethal dose; ED50: Median effective dose; ER50: Median effective ratio. 

aMedian lethal dose was defined as the dose of venom (µg/g) at which 50% of mice died. The 95% confidence limits are included in parenthesis. bMedian effective dose was defined as the dose of antivenom (µl) at which 50% of mice survived. The 95% confidence limits are included in parenthesis. cMedian effective ratio was defined as the ratio of venom (mg) to antiserum (ml) at which 50% of mice survived. dPotency, P was defined as the neutralization potency of the antivenom (mg venom/ml antiserum) at which the amount of venom (mg) was completely neutralized by one ml of antivenom. eTan et al. (2015) fTan et al. (2016) gTan et al. (2016) hTan et al. (2016) iTan et al. (2016) jTan et al. (2016) kTan et al. (2016) lTan et al. (2016) mTan et al. (2016) nTan et al. (2016) oTan et al. (2016) pTan et al. (2016) qTan et al. (2016) rTan et al. (2016) sTan et al. (2016) tTan et al. (2016) uTan et al. (2016) vTan et al. (2016) wTan et al. (2016) xTan et al. (2016) yTan et al. (2016) zTan et al. (2016) #Tan et al. (2016) &Tan et al. (2016) **Tan et al. (2016)
Results and Discussion
Neutralization of neurotoxic venoms by the pan-specific antiserum and their toxin profiles.

The 10 neurotoxic venoms hereby tested are shown in Table 1. The list includes venoms of the coral snake (Micrurus nigrocinctus), the most medically important elapid in Central America, the yellow-lipped sea krait (Laticauda colubrina), and the beaked sea snake (Hydrophis schistosus) distributed from Australian waters to the Arabian Sea. Other venoms tested include those of the tiger snake (Notechis scutatus), the king brown snake (Pseudechis australis) and the coastal taipan (Oxyuranus scutellatus), which are classified within WHO Category 1 most medically important snakes from Australia and Papua New Guinea. In addition, neutralization of venoms of the African species black mamba (Dendroaspis polylepis), the green mamba (Dendroaspis angusticeps), the

Table 2. Profiles of major lethal toxins of 10 neurotoxic venoms from four different continents. Abbreviations: Ven. Supplies: Venom Supplies; 3FTx: three-finger toxins; SNTX: short neurotoxin; LNTX: long neurotoxin; CTX: cytotoxin/cardiotoxin; κ-BTX: kappa-bungarotoxin; KSPI: Kunitz-type serine protease inhibitor; SVMP: snake venom metalloproteinase; N.A.: Not available. *Proteomic data is not available. †Quantitative data is not available.

possible basis for the wide para-specificity observed, and its potential application for the preparation of ‘universal neurotoxic antivenom’ are proposed.
western green mamba (Dendroaspis viridis), and the Senegalese cobra (Naja senegalensis) was assessed. All these snakes, except Micrurus nigrocinctus, are within WHO Category 1 species, i.e. 'highly venomous snakes which are common or widespread and cause numerous snake-bites, resulting in high levels of morbidity, disability or mortality'. M. nigrocinctus is in WHO Category 2 snakes, i.e. 'highly venomous snakes capable of causing morbidity, disability or death, for which exact epidemiological or clinical data may be lacking; and/or which are less frequently implicated but is capable of inducing fatal bites'.

From the median lethal dose (LD$_{50}$) results, the coastal taipan (O. scutellatus) was the most lethal (LD$_{50} = 0.03$ µg/g) among the 10 venoms, while the least toxic was D. angusticeps venom (Tanzania) with LD$_{50}$ of 1.53 µg/g (Table 1).

Of the ten venoms studied, nine of them, including those from the two sea snakes, the Central American coral snake and the Australian snakes were cross-neutralized, and so were those of two African mambas (D. viridis and D. polyplepis) and one African cobra (N. senegalensis). Only the green mamba (D. angusticeps) venom was not neutralized by the pan-specific antiserum. The antiserum most effectively neutralized the venom of N. senegalensis with a Potency (P) of 0.185 mg venom/ml antiserum, followed by the venoms of M. nigrocinctus, the two African mambas and the three Australian elapids. The P value of antiserum against the sea krait (L. colubrina) venom underscored that it was still capable of neutralization. Thus the results showed that 9 out of ten neurotoxic venoms were neutralized by the pan-specific antiserum; only the venom of D. angusticeps was not neutralized even with 200 µl of the antiserum, a dose that was the maximum volume permissible for bolus intravenous injection into mice.

It is relevant to analyse the neutralization results vis-à-vis the proteomic profiles previously reported for these venoms. Table 2 depicts the major toxic components described for these venoms, with the exception of N. senegalensis, whose venom proteome has not been characterized. The proteomics toxin profiles show the major toxic (lethal) components of each of these 10 venoms. Seven of them contain short (Type I) and long (Type II) α-neurotoxins, which belong to the three-finger toxin family (3FTx). The α-neurotoxins in these seven venoms are highly toxic and could lead to neuromuscular paralysis and death.

Neurotoxicity caused by P. australis venom has been demonstrated and it was more potent to diapids than to synapsids. Moreover, a short- and a long α-neurotoxins had been reported from P. australis venom (UniProt database entries: P25497 and P14612, respectively). The toxins were present at very low level that probably explained its non-detection in the proteomic study, and in our in vitro assay based on T. californica nAChR binding (Fig. 1). However, the α-neurotoxins were highly lethal to mice (LD$_{50}$ < 0.1 µg/g), and along with the myotoxic and anticoagulant PLA$_2$s probably contribute to the venom lethality in mice, being therefore possible targets of cross-neutralization by the pan-specific antiserum.

All nine venoms with available proteomic information contained phospholipases A$_2$ (PLA$_2$s), some of which are basic PLA$_2$s, that contribute to presynaptic neurotoxicity in O. scutellatus (known as taipoxin) and N. scutatus (known as notoxin) venoms, and hemolytic, anticoagulant and myotoxic activities in P. australis venom. Besides, the myotoxic PLA$_2$ was also found abundantly in the sea snake (H. schistosus) venom, which causes rhabdomyolysis and nephrotoxicity in envenomation.

Both lethal α-neurotoxins and presynaptic PLA$_2$s are present in the venom of H. schistosus and N. scutatus. In addition to α- and β-neurotoxins, procoagulant serine proteases in the venoms of Australian elapids (O. scutellatus and N. scutatus) can cause hemostatic alterations which may lead to bleeding or thrombosis, although it is likely that neurotoxins are the main culprits of lethality in these venoms. The lethal toxins present in the nine venoms were presumably neutralized by the pan-specific antiserum, as evidenced by neutralization results.

It should be mentioned that the pan-specific antivenom was prepared with the aim of neutralizing lethal neurotoxins (mainly α- and β-neurotoxins) and not against the high molecular weight enzymes (e.g. prothrombin activators) which were filtered out during the preparation of immunogens. As such, the pan specific antiserum was not tested for neutralization of these activities associated with high molecular mass components.

Regarding the three mamba venoms, α-neurotoxins are present in D. viridis and D. polyplepis. In addition, fasciculins, members of the 3FTx family which induce fasciculations by inhibiting acetylcholinesterase, were found in D. viridis and D. angusticeps venoms. Dendrotoxins, which have homology to Kunitz-type proteinase inhibitors and block voltage-dependent potassium channels, are typical of mamba venoms, with highest...
Table 3. Profiles of major lethal toxins of 16 heterologous elapid venoms tested in previous study (Ratanabanangkoon et al., 2016). Abbreviations: 3FTx: three-finger toxins; SNTX: short (Type I) neurotoxin; LNTX: long (Type II) neurotoxin; CTX: cytotoxin/cardiotoxin; α-BTX: alpha-bungarotoxin; κ-BTX: kappa-bungarotoxin; β-BTX: beta-bungarotoxin; KSPI: Kunitz-type serine protease inhibitor; SVMPS: snake venom metalloproteinase; N.A.: Not available. *Proteomic data is not available. #Quantitative data is not available.

| No | Elapid venoms (locality/source) | Major Lethal Toxins (numbers of proteoforms reported are shown in parentheses) | 3FTx (%) | Phospholipase A₂ (%) | Kunitz | SVMPS | Ref. |
|----|---------------------------------|------------------------------------------------|----------|----------------------|--------|-------|------|
| 1  | Naja oxana* (Pakistan) (Wild caught specimens) | | | | | | |
| 2  | Naja sumatraensis (Seremban, Malaysia) (Wild caught specimens) | | | | | | |
| 3  | Naja siamensis (Thailand) (Latoxan, France) | | | | | | |
| 4  | Naja naja* (India) (Latoxan, France) | | | | | | |
| 5  | Naja naja* (Sri Lanka) (Wild caught specimens) | | | | | | |
| 6  | Naja naja* (Pakistan) (Dr Naem Qairazi, Sind) (Wild caught specimens) | | | | | | |
| 7  | Naja haje** (Morocco) | ✓ | | | | | |
| 8  | Naja nigricollis* (Cameroon) (Latoxan, France) | ✓ | | | | | |
| 9  | Bungarus caeruleus (Pakistan) (Wild caught specimens) | | | | | | |
| 10 | Bungarus caeruleus (Sri Lanka) (Serpentarium, University of Colombo) | Chromatographic profile of Sri Lankan B. caeruleus did not exhibit significant variation compared to Pakistani B. caeruleus | | | | | |
| 11 | Bungarus caeruleus (India) (Latoxan, France) | Chromatographic profile of Indian B. caeruleus did not exhibit significant variation compared to Pakistani B. caeruleus | | | | | |
| 12 | Bungarus fasciatus (Thailand) (Queen Saovabha Memorial Institute) | | | | | | |
| 13 | Ophiophagus hannah (Seremban, Malaysia) (Wild caught specimens) | | | | | | |
| 14 | Ophiophagus hannah (Pakistan) (Wild caught specimens) | | | | | | |
| 15 | Naja melanoleuca* (Uganda) (Latoxan, France) | | | | | | |
| 16 | Naja nivea* (North Africa) (Latoxan, France) | | | | | | |

Concentration in the venom of D. polylepis. Both dendrotoxins and fasciculins were probably not neutralized by the pan-specific antiserum since these toxins are not present in the immunogen mix. α-Neurotoxins are the most lethal toxins of D. polylepis venom, with dendrotoxins playing a minor role in lethality. This explains why the lethality of this venom was neutralized by the pan-specific antiserum even though the dendrotoxins were unlikely neutralized.

D. angusticeps venom was the only one not neutralized by the pan-specific antiserum. From its proteome, forty-two different proteins were detected, among which 3FTxs were the most abundant, followed by the Kunitz-type proteinase inhibitor family. However, no α-neurotoxin was identified in the venom which is in agreement with an in vitro potency assay based on nAChR binding (Fig. 1). None of the venom HPLC fractions was lethal to mice at the doses tested. Thus, it was proposed that the lethality of the venom was due to the synergistic action of various components, such as fasciculins and dendrotoxins, and probably other synergistically-acting toxins. It is not surprising that the pan-specific antiserum did not neutralize the lethal effects of the venom since the toxins of the venom were not present in the immunogen mix, and simultaneous neutralization of various synergistic acting toxins are required in order to neutralize the lethality of the venom.
Proteomics data indicate that α-neurotoxins in *N. nigricollis* venom was only 0.4% of the total HPLC separated proteins, with higher amounts of cytotoxins (72.8%) and PLA₂₅ (21.9%)⁷⁷. The antiserum most likely contains antibodies against these components in this spitting cobra venom probably due to the presence of similar toxins in the venoms used in the immunizing mix.

In the case of *N. sengaleensis* venom, no proteomics data are available. However, clinical cases are associated with neuromuscular paralysis and respiratory failure²⁸, suggesting that α-neurotoxins are likely to play a key role in the overall toxicity. This venom was effectively neutralized by the pan-specific antiserum, underscoring that these lethal toxins were immunorecognized by the antibodies. Nevertheless, caution should be exerted when extrapolating data from mouse experiments to the human situation when studying venom-induced neurotoxicity²⁹.

Table 3 shows the proteomics toxin profiles of the 16 heterologous venoms previously shown to be neutralized by the pan-specific antiserum. Ten of them are from species of the genus *Naja*, characterized by the presence of short (Type I) and long (Type II) α-neurotoxins and cytotoxins. Venoms from species of *Bungarus*, e.g. *B. candidus* and *B. multicinctus*, contain both pre-synaptic β- and post-synaptic α-neurotoxins.⁵⁰,⁵¹ In the case of *Ophiophagus hannah*, its venom contains α-neurotoxins but not β-neurotoxins.⁶² These toxins, except for cytotoxins, are highly lethal in mice and are known to be the cause of death in elapid envenomations. On the basis of our observations, they were likely neutralized by the antibodies in the pan-specific antiserum.

Thus, the pan-specific antiserum neutralized most, if not all, the potentially lethal toxins in the 25 heterologous neurotoxic venoms tested, hence stressing the value of using fractions enriched with various lethal toxins of several venoms in the immunization process. Another alternative proposed to raise an antiserum of high neutralizing coverage against neurotoxic venoms includes the use of recombinant consensus short α-neurotoxins as immunogen. In this case, however, the antiserum is not effective in the neutralization of presynaptic β-neurotoxins, and recombinant consensus PLA₂ neurotoxins would need to be added to the immunizing mix to neutralize venoms whose toxicity is driven by β-neurotoxins.

The preparation of this wide para-specific antiserum involved immunization of horses with 12 toxin fractions/venoms of 6 species of selected cobras (*Naja spp.*) and kraits (*Bungarus spp.*) inhabiting various countries of Asia. Table 4 presents the toxin profiles of these 12 venoms. These elapid venoms contain a diverse set of toxins, such as short and long α-neurotoxins, β-neurotoxins and cytotoxins as the major lethal toxins. Table 4 shows the number of isoforms of each type of these toxins in these 12 venoms. Altogether, there are about 23 isoforms of short (Type I) α-neurotoxins, 17 isoforms of long (Type II) α-neurotoxins and about 15 isoforms of PLA₂ β-neurotoxins which are exposed to the horses. These large numbers of toxin isoforms are likely to contain numerous epitopes of these lethal toxins. It is therefore conceivable that the immune system of the horses generated a diverse set of paratopes against epitopes of widely diverse toxins of numerous neurotoxic venoms, which is termed ‘diverse toxin repertoire’. The following considerations may form the bases for explaining this phenomenon:

(a) The most lethal components in the majority of these neurotoxic venoms are the post-synaptically-acting α-neurotoxins (Tables 2, 3 and 4). For some venoms, e.g. *Bungarus spp.* and *O. scutellatus*, highly lethal β-neurotoxins are also relevant to human envenomation.²²,²⁴-³⁰ For simplicity, this discussion will be confined to the case of α-neurotoxins, which constitute the main lethal factors of many, but not all, elapid venoms.⁹⁹ α-neurotoxins are small polypeptides of about 61–62 amino acids with 4 disulfide linkages (short α-neurotoxins) or 66–75 amino acids with 5 disulfide linkages (long α-neurotoxins)⁵⁵. They adopt a planar structure similar to a 3-finger configuration and are referred to as three-finger toxins (3FTxs)⁶⁸. The amino acid sequences of the over 400 α-neurotoxins from snakes have been described; the top 100 of these sequences share about 66.8% identity.⁴¹ All of these α-neurotoxins bind specifically and strongly to the α-subunits of nAChR at the motor endplate in the neuromuscular junction.⁴⁰,⁴²,⁴³ Thus all these toxins share structural and functional homology.

(b) Each elapid venom may contain several α-neurotoxins (short, long, dimers, precursors, etc.) that show sequence variations⁴⁴. Most of the venoms contain 1–5 α-neurotoxin isoforms (Table 4); therefore, the total number of α-neurotoxin isoforms in the immunogen mixture may reach several dozens. These numerous α-neurotoxin isoforms together contain a large number of toxin epitopes to which the horses were exposed to, with a vast number of antibody paratopes generated against these epitopes. Hence, the diversity of α-neurotoxin isoforms is the strength in this immunization strategy, as it contributes to generate a wide repertoire of antibodies.

(c) Given their small molecular size and constraint to form a biologically active conformation, it is likely that each α-neurotoxin contains a relatively small number of dominant epitopes on its surface, as shown for venoms of *Dendroaspis spp.*, using a high-throughput microarray analysis⁴⁶, with each epitope covering an area of 6–7 amino acid residues⁷⁶. Some of the epitopes from homologous toxins are conserved for structural and functional reasons. Because of the high sequence identity, some of these epitopes are expected to be structurally similar, though not identical, and thus explain some degree of immunochemical cross reactivity of antisera⁴⁷-⁴⁹.

(d) In the case of monospecific polyclonal antisera raised against a single neurotoxic venom, they are likely to contain high affinity antibodies against the α-neurotoxins of the homologous venom. Some of these
| No | Elapid venoms (locality/source) | Potential Lethal Toxins (numbers of proteoforms detected are shown in brackets) | 3FTx (%) | LNTX | CTX | α-BTX | κ-BTX | Phospholipase A_2 (%) | Acidic | Basic | Neutral | β-BTX | Kunitz | SVMP | Ref. |
|----|--------------------------------|---------------------------------------------------------------------------------|----------|------|-----|-----|-----|----------------|--------|-------|---------|-------|-------|------|------|
| 1  | Naja kaouthia (Thailand) (QSMI, Thailand) | 7.7 (2) 33.3 (1) 27.6 (6) — — 12.2 (2) — — — — — — — | 2.5 (3) |
| 2  | Naja kaouthia (Wild caught specimens) | 4.2 (3) 3.9 (1) 45.7 (6) — — 23.5 (4) — — — — — — — | 0.5 (1) 3.3 (4) |
| 3  | Naja kaouthia (Vietnam) (Dr. Trinh Xuan Kiem) (Wild caught specimens) | 9.2 (3) — 44.9 (6) — — 17.4 (2) — — — — — — | <0.1 (1) 1.6 (3) |
| 4  | Naja philippinensis (The Philippines) (Latoxan, France) | 44.6 (4) — 21.3 (8) — — 18.7 (4) 0.5 (1) 3.7 (1) — — | 3.9 (4) |
| 5  | Naja spatulata (Indonesia) (Latoxan, France) | 7.9 (5) 0.5 (3) 48.1 (11) — — 23.1 (6) 5.9 (1) 2.3 (1) — — | 0.2 (1) 1.3 (10) |
| 6  | Naja atra (China) (Wild caught specimens) | 11.3 (2) — 65.3 (4) — — 12.2 (2) — — — — — — | 1.5 (2) |
| 7  | Naja atra (Western Taiwan) (Undifferentiated) | 23.5 (Undifferentiated) (2) 52.9 (6) — — 16.8 (1) — — — — — — | 1.7 (2) |
| 8  | Bungarus multicinctus (China) (Wild caught specimens) | — — — 6% (1) 2.4 (3) 3.3 (1) — — | 58.6 (4) 0.5 (2) 0.1 (2) |
| 9  | Bungarus multicinctus (Taiwan) (Wild caught specimens) | ✓ (1) ✓ (7) — — — — ✓ (4) (Undifferentiated) | ✓ (1) |
| 10 | Bungarus candidus (Northeast Thailand) (QSMI, Thailand) | — — — — — — — — | — | — | — | — | — | — | — | N.A. |
| 11 | Bungarus candidus (Southern Thailand) (QSMI, Thailand) | ✓ (1) ✓ (3) ✓ (2) ✓ (6) ✓ (2) ✓ (3) ✓ (4) — — ✓ (3) ✓ (2) | ✓ (1) |
| 12 | Bungarus candidus (Indonesia) (Biopharma, Bandung) (Wild caught specimens) | — ✓ (1) ✓ (1) — ✓ (2) — — ✓ (2) — — ✓ (3) — | ✓ (2) |

Table 4. Toxin profiles of 12 elapid venoms used as immunogens for production of horse pan-specific antisera. Abbreviations: 3FTx: three-finger toxins; SNTX: short neurotoxin; LNTX: long neurotoxin; CTX: cytotoxin/cardiotoxin; α-BTX: alpha-bungarotoxin; κ-BTX: kappa-bungarotoxin; β-BTX: beta-bungarotoxin; KSPI: Kunitz-type serine protease inhibitor; SVMP: snake venom metalloproteinase; N.A.: Not available. 

®Proteomic data is not available. ◊Quantitative data is not available. °Venom source different from the species tested in the previous study.
antibodies may cross react with heterologous α-neurotoxins due to epitope structural similarity. Being heterologous, these cross reacting antibodies in monospecific antisera are likely to have lower affinity/avidity^{26,28} and by themselves may not bind effectively and neutralize the heterologous α-neurotoxins. This could be a reason for the low cross-neutralization of monospecific antivenoms usually observed^{23}.

(c) The ’diverse toxin repertoire’ immunization strategy using a large number of diverse α-neurotoxin epitopes to immunize the horses^{11} is likely to result in the production of numerous paratopes in the antibodies against these epitopes which might be shared with other heterologous α-neurotoxins, hence contributing to its broad specificity. Moreover, it has been shown that a single antibody could adopt different conformations of its paratope to bind different epitopes, thus enhancing its antigenic coverage^{31}.

(f) The more diverse the paratopes of the antisera antibodies, the better chance for some of them to interact with the epitopes of the heterologous α-neurotoxins. These interactions, albeit with lower affinity should, through cross-linking and lattice formation^{24}, result in antisera with higher avidity leading to more effective neutralization of diverse heterologous neurotoxic venoms^{33}. Similar situations may occur with the highly lethal presynaptic β-neurotoxins^{32} and other types of venom toxins when using a variety of venoms in the immunizing mixture.

(g) The large pool of diverse antibody paratopes makes it likely that high affinity antibodies are present to interact effectively with a variety of α-neurotoxins. This is crucial because, due to steric hindrance, no more than two antibody molecules can interact simultaneously with one toxin molecule (Supplementary Fig. 1).

Whether or not the proposed bases for the wide para-specificity of our antiserum are correct, the results of these studies show that this is the widest cross-neutralizing antiserum ever reported against neurotoxic snake venoms from wide geographical distribution. Our results represent a proof of concept that an antiserum with wide spectrum of cross-neutralization against elapid venoms can be used.

In this connection, it would be interesting to apply the ‘diverse toxin repertoire’ immunization strategy to prepare pan-specific antisera against other snake venoms in which different toxicological effects predominate, such as hemorrhagic and procoagulant venoms in sub-Saharan Africa^{23,24}. The genus-wide analysis of venom composition and toxicity of these venoms to identify the lethal toxins^{24} followed by use of the combined toxin fractions to immunize horses, is likely to result in widely para-specific antiserum against these snake venoms.

Further possible improvements of the pan-specific antiserum against neurotoxic venoms. As shown in Tables 1, 2 and 3, the antiserum could neutralize lethality of 25 heterologous venoms, but its neutralizing potency against some of them is rather low. This becomes a problem especially when dealing with species that inject a large volume of venom in a bite. However, the potency of the antiserum can be improved by a concentration process during plasma fractionation. For example, the antivenom produced from horse sera against the recombinant short chain α-neurotoxins was fractionated by caprylic acid precipitation and used at 50 mg/ml^{33}; hence, the protein in this antivenom most likely contained only IgG and IgG_{2}. Since horse hyperimmune sera have an average protein concentration at 62.75 ± 0.33 mg/ml, and IgG + IgGT represent about 37% of the total serum protein^{31}, the antibody in the antivenom prepared by de la Rosa et al^{33} was about 2.01 fold concentrated as compared to the crude horse serum. Also, the commercial antivenoms produced by the Thai Red Cross in the form of F(ab’), resulted from about three fold concentrates of serum IgG. After such concentration process, the present horse pan-specific antiserum could have higher neutralizing activity against the lethality of many neurotoxic venoms. This may not only increase the potency against the venoms tested, but also provide neutralization of additional elapid venoms.

There is a growing interest in the development of recombinant antivenoms^{55,56}. This involves, for example, the preparation of animal- or human-derived monoclonal antibodies against the lethal components of venoms. Proofs of concept of this strategy have been published^{57,58}. One major requirement of this approach is that the major lethal toxin(s) of the venom must be identified and used for antibody selection. When more than one toxin is relevant in a particular venom, there is a need to generate additional antibodies for a successful neutralization. Since these antibodies are produced against one or few toxins, a challenging issue for this strategy is to ensure the neutralization of heterologous toxins present in other venoms. Such problem is overcome by the present ‘diverse toxin repertoire’ immunization approach by including the toxin/venom fractions of a variety of venoms in the immunogen mix, thus ensuring cross-reactivity, as described in this work.

It should be possible to further increase the para-specificity of the antiserum by including additional venom toxin fractions in the immunization mix. For example, inclusion of toxin fractions of some African mamba venoms (D. angusticeps and D. viridis) and some American coral snakes (e.g., Micrurus spp.) could increase the neutralizing scope of the antiserum. Noteworthy, the amount of toxin fraction of each venom used in the immunization was just a few micrograms (12 μg of each venom in the primary immunization), and the total protein amount of such an immunization mix would still be less than one mg^{11}. This amount of venom toxins, once emulsified in Freund’s oil adjuvants, does not cause major harm to the horses^{23}. By carefully selecting the venoms and fractions to be added to the immunizing mix it should be possible to expand the scope of coverage of neurotoxic venoms, ideally to neutralize the most important elapid venoms in the world.

Conclusion
Snakebite envenomation is a WHO classified category A Neglected Tropical Diseases, i.e. a disease of highest importance. Consequently, WHO has launched a global strategy with the aim of reducing the disease burden of snakebite envenomation by 50% by the year 2030^{60}. One of the four pillars of this strategy is to ensure safe and effective treatments, particularly referring to antivenoms, which represent the only scientifically-validated therapy for these envenomings. As shown in this work, a pan-specific antivenom against neurotoxic venoms would be a powerful therapeutic tool to save lives of people suffering these envenomings in different parts of the world,
by neutralizing a wide spectrum of neurotoxic snake venoms which otherwise require region- or species-specific antivenoms for treatment. We showed that the production of such an antivenom prototype is feasible and practical through exposing horses to a novel ‘diverse toxin repertoire’ of 12 neurotoxic snake toxins/venoms. The antiserum exhibited a wide para-specificity by neutralizing at least 36 neurotoxic venoms of snakes of 10 genera from four continents. The pool of diverse toxin antigens in the immunogen mix enabled the production of diverse antibody paratopes, which facilitate the interaction of the antibodies with the epitopes of various neurotoxins from homologous as well as heterologous snake venoms. With further optimization on the immunogen mix, the ‘diverse toxin repertoire’ immunization strategy could result in antiserum with even broader para-specificity, ideally to cover most or all medically important neurotoxic venoms worldwide.

Materials and Methods

Venoms and antiserum. Dendroaspis polylepis, D. angusticeps, D. viridis and Naja senegalensis venoms were obtained from Latoxon (Valence, France); Laticauda colubrina, Pseudechis australis, Oxyuranus scutellatus and Notechis scutatus venoms were obtained from Venom Supplies Pty Ltd (Australia). Hydrophis schistosus venom was provided by Dr. CH Tan, and Micruirus nigrocinctus venom was provided by Prof. José María Gutiérrez. These two venoms were obtained from several specimens kept in captivity (M. nigrocinctus) or captured wild (H. schistosus).

Naja kaouthia (Thailand) principal post-synaptic neurotoxin 3 (NK3) was purified as described by Karlsson et al.61. The pan-specific antiserum used in the present study was from the same batch as that obtained from horses immunized with mixtures of venoms and venom fractions11 using the protocol briefly described below.

Chemicals. All chemicals and biochemicals were from Sigma Chemical Co. (St Louis, Missouri, USA) unless otherwise stated.

Animal care and experimentation. Experiments carried out in horses regarding care, bleeding and immunization were approved by the Animal Care and Use Committee of the Faculty of Veterinary Science, Mahidol University, Protocol and clearance no.MUVS-2012-69 in accordance with the Guidelines of the National Research Council of Thailand.

Albino mice (male ICR strain, 20–30 g) were supplied by the Animal Experimental Unit (AEU), Faculty of Medicine, University of Malaya, and handled according to the Council for International Organization of Medical Sciences (CIOMS) guideline on animal experimentation62. The animal use was approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Malaya (Reference number: 2018-211218/MOL/R/TKY).

Preparation of the pan-specific antiserum. Preparation of the pan-specific antiserum was described previously11. Briefly, horses were immunized with a mixture of toxin fraction/venoms of 12 elapids mostly of Naja spp. and Bungarus spp. inhabiting different geographical locations of Asia11. The toxin fractions of Naja spp. venoms were prepared by ultrafiltration of each venom solution (prepared in 100 mM ammonium acetate, pH 5.0, 1 mg/ml) through 30 kDa molecular weight cut off (MWCO) ultrafiltration membranes while those of the Bungarus spp. venoms were filtered through 50 kDa MWCO filters. The toxin fractions (12 µg from each venom) were combined and mixed with (1:1 v/v) and emulsified in Complete Freund Adjuvant. The primary immunization was carried out using the ‘low dose, low volume multi-site’ immunization protocol59,63 under which the immunogen was injected subcutaneously around the horse’s neck at 20 sites in a volume of 0.1 ml/site. After several booster immunizations at 2 weeks intervals, the horses were bled and the sera prepared by centrifugation of the clotted blood at 800 × g for 15 minutes. The sera were kept at −20°C.

Estimation of α-neurotoxins present in neurotoxic venoms by their binding to solubilized Torpedo californica nicotinic acetylcholine receptor (nAChR). The presence of α-neurotoxins in venoms was estimated by the venom-mediated inhibition of the binding of purified nAChR to immobilized elapid post-synaptic neurotoxins, as described previously60. The basic procedure of the assay is to incubate (25°C, 60 min) varying amounts (0.03–10)µg/ml of a tested neurotoxic venom with a pre-determined optimal amount (0.707 µg/ml) of soluble nAChR purified from T. californica electroplax. After incubation, the excess nAChR was estimated by adding the mixture to microtiter wells coated with 15 µg/ml of purified NK3. The amount of nAChR bound to the immobilized NK3 in the wells was estimated by adding anti-nAChR serum at 1:1600 dilution followed by a 1:4500 dilution of goat anti-rat IgG-enzyme conjugated HRP and enzyme substrate. In the absence of the tested neurotoxic venom, the binding of nAChR was considered as 100%. If the tested neurotoxic venom contained α-neurotoxin which could specifically interact with nAChR, the percent binding of the receptor to the NK3 immobilized plate is reduced and can be calculated using the following formula:

\[
\% \text{nAChR binding} = \frac{(OD \text{ Sample} - \ OD \ Ag \ control)}{(OD \text{ Max} - \ OD \ control)} \times 100
\]

‘OD Max’ represents the binding of optimized nAChR to NK3 immobilized plate without incubation with each crude elapid venom.

‘OD Ag control’ represents the binding background of optimized nAChR and NK3 immobilized plate.

‘OD Sample’ represents the binding of optimized nAChR to the NK3 immobilized plate after the nAChR was inhibited by α-neurotoxin at various concentrations of crude elapid venom.
**Determination of venom lethality and antiserum efficacy of neutralization in mice.** Venom lethality (median lethal dose, LD$_{50}$) and the median effective doses (ED$_{50}$) of the pan-specific antiserum against the venoms tested were determined and analyzed as previously reported$^{11}$ and are briefly described below.

**Determination of LD$_{50}$.** The median lethal dose (LD$_{50}$) of a venom was determined by i.v. injection of varying doses of the venom into the caudal vein of the mice (20–30 gm, n = 4 per venom dose). The result was obtained at 24 hr after injection and LD$_{50}$ was determined using Probit analysis$^{15}$.

**Lethality neutralization assay.** In the lethality neutralization assay, a challenge dose of 5xLD$_{50}$ of a venom was mixed with various doses of the antiserum (diluted in normal saline) and pre-incubated at 37 °C for 30-minutes. The mixture was centrifuged at 10,000 × g for 5 minutes and aliquots of the supernatant, containing 5 LD$_{50}$s of venom, were injected intravenously into the caudal vein of the mice (n = 4 per dose). If the mice did not fully survived 5x LD$_{50}$ of venom dose with 200µl of antiserum, the challenge dose was reduced to 2.5x LD$_{50}$ and subsequently to 1.5x LD$_{50}$ if needed. In all experiments, the control groups of mice, regardless of whether 5x, 2.5x or 1.5x LD$_{50}$ challenge dose without the use of the antiserum died.

The neutralization potency (P) of the antiserum, defined as the amount of venom completely neutralized per unit volume of antiserum, was expressed as previously described$^{89}$.

Received: 30 November 2019; Accepted: 30 April 2020;
Published online: 09 July 2020

**References**

1. Chippaux, J. P. Snake-bites: appraisal of the global situation. *Bull. World Health Organ.* **76**, 515 (1998).
2. Kasturiratne, A. et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. *PLoS Med.* **5**, e218 (2008).
3. Gutiérrez, J. M. et al. Snakebite envenoming. *Nat. Rev. Dis. Prim.* **3**, 17063 (2017).
4. Williams, D. J. et al. Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. *J. Proteom.* **74**, 1735–1767 (2011).
5. Gauthavorn, S. Toxicities of Thailand snake venoms and neutralization capacity of antivenin. *Toxicon* **7**, 239–241 (1989).
6. Lingam, T. M. C., Tan, K. Y. & Tan, C. H. Thai Russell’s viper monospecific antivenom is immunoreactive and effective in neutralizing the venom of Daboia siamensis from Java, Indonesia. *Toxicon* **168**, 95–97 (1999).
7. Tan, C. H., Liew, J. L., Tan, K. Y. & Tan, N. H. Assessing SABU (Serum Anti Bisa Ular), the sole Indonesian antivenom: A proteomic analysis and neutralization efficacy study. *Sci. Rep.* **6**, 37299, https://doi.org/10.1038/srep37299 (2016).
8. Tan, C. H. et al. Cross reactivity and lethality neutralization of venoms of Indonesian Trimeresurus complex species by Thai Green Pit Viper Antivenin. *Toxicon* **140**, 32–37 (2017).
9. Harrison, R. A., Hargreaves, A., Wagstaff, S. C., Faragher, B. & Laloo, D. G. Snake envenoming: a disease of poverty. *PLoS Negl Trop Dis* **3** (2009).
10. Longbottom, J. et al. Vulnerability to snakebite envenoming: a global mapping of hotspots. *The Lancet* (2018).
11. Ratanabanangkoon, K. et al. A simple and novel strategy for the production of a Pan-specific antiserum against elapid snakes of Asia. *PLoS Negl. Trop. Dis.* **10**, e0004565, https://doi.org/10.1371/journal.pntd.0004565 (2016).
12. Iwanaga, S. S. T. Enzymes in Snake Venom. In *Snake Venoms* (2ed Lee C-Y). Springer Berlin Heidelberg (1979).
13. WHO. World Health Organization. Guidelines for the production, control and regulation of snake antivenom immunoglobulins. Geneva: WHO 134 (2018).
14. Hart, A. J., Isbister, G. K. & Hodgson, W. C. In vitro neurotoxic effects of Pseudocissus spp. venoms: A comparison of avian and murine skeletal muscle preparations. *Toxicon* **63**, 112–115 (2013).
15. Georgieva, D. et al. Pseudocissus australis venomics: adaptation for a defense against microbial pathogens and recruitment of body receptors. *J. Proteom. Res.* **10**, 2440–2441 (2011).
16. Takasaki, C., Suzuki, J. & Tamiya, N. Purification and properties of several phospholipases A2 from the venom of Australian king brown snake (Pseudocissus australis). *Toxicon* **28**, 319–327 (1990).
17. Herrera, M. et al. Comparative proteomic analysis of the venom of the taipan snake, Oxyuranus scutellatus, from Papua New Guinea and Australia: Role of neurotoxic and procoagulant effects in venom toxicity. *J. Proteom.* **75**, 2128–2140 (2012).
18. Halpert, J. & Eaker, D. Amino acid sequence of a presynaptic neurotoxin from the venom of Notechis scutatus scutatus (Australian tiger snake). *J. Biol. Chem.* **250**, 6990–6997 (1975).
19. Sharp, P. I., Berry, S. L., Spence, J. & Howden, M. A basic phospholipase A from the venom of the Australian king brown snake (Pseudocissus australis) showing diverse activities against membranes. *Comp. Biochem. Physiol. B* **92**, 501–508 (1989).
20. Tan, C. H., Tan, K. Y., Lima, S. E. & Tan, N. H. Venomics of the beaked sea snake, Hydrophis schistosus: A minimalistic toxin arsenal and its cross-neutralization by heterologous antivenoms. *J. Proteom. Res.* **12**, 126, 121–130, https://doi.org/10.1021/pr1005035 (2015).
21. Tan, C. H., Tan, K. Y. & Tan, N. H. Revisiting Notechis scutatus venom: on shotgun proteomics and neutralization by the “bivalent” Sea Snake Antivenom. *J. Proteom. Res.* **144**, 33–38, https://doi.org/10.1021/pr60080e4 (2016).
22. Harris, J., Grubb, B., Maltin, C. & Dixon, R. The neurotoxicity of the venom phospholipases A2, notexin and taipoxin. *Exp. Neurol.* **161**, 517–526 (2000).
23. Lauridsen, L. P., Laustsen, A. H., Lomonte, B. & Gutiérrez, J. M. Toxinovemetics and antivenom profiling of the Eastern green mamba snake (*Dendroaspis angusticeps*). *J. Proteom.* **136**, 248–261 (2016).
24. Ainsworth, S. et al. The medical threat of mamba envenoming in sub-Saharan Africa revealed by genus-wide analysis of venom composition, toxicity and antivenomics profiling of available antivenoms. *J. Proteom.* **172**, 173–189 (2018).
25. Laustsen, A. H., Lomonte, B., Loehle, B., Fernández, J. & Gutiérrez, J. M. Unveiling the nature of black mamba (*Dendroaspis polylepis*) venom through venomics and antivenom immunoprofiling: Identification of key toxin targets for antivenom development. *J. Proteom.* **119**, 126–142 (2015).
26. Ratanabanangkoon, K. et al. A novel in vitro potency assay of antiserum against Thai Naja kaouthia based on nicotinic acetylcholine receptor binding. *Sci. Rep.* **7**, 1–8 (2017).
27. Petras, D. et al. Snake Venomics of African Spitting Cobras: Toxin Composition and Assessment of Congeneric Cross-Reactivity of the Pan-African EchiTAb-Plus-ICP Antivenom by Antivenomics and Neutralization Approaches. *J. Proteom. Res.* **10**, 1266–1280, https://doi.org/10.1021/pr101040f (2011).
28. WHO. World Health Organization. Regional Office for Africa. Guidelines for the prevention and clinical management of snakebite in Africa: Mauritius, http://apps.who.int/medicinedocs/documents/s17810en/s17810en.pdf (accessed on 20th Aug 2018) (2010).
29. Maduwage, K., Silva, A., O’Leary, M. A., Hodgson, W. C. & Isbister, G. K. Efficacy of Indian polyvalent snake antivenoms against Sri Lankan snake venoms: lethality studies or clinically focussed in vitro studies. Sci. Rep. 6, 26778 (2016).
30. Rusnili, M. R. A. et al. Variations in neurotoxicity and proteome profile of Malayan krait (Bungarus candidus) venoms. PLoS one 14 (2019).
31. Shan, L. L. et al. Proteomic characterization and comparison of venoms from two elapid snakes (Bungarus multicinctus and Naja attra) from China. J. Proteom. 138, 83–94, https://doi.org/10.1016/j.jprot.2016.02.028 (2016).
32. Tan, C. H., Tan, K. Y., Fung, S. Y. & Tan, N. H. Venom gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah). BMC genomics 16, 887, https://doi.org/10.1186/s12864-015-1828-2 (2015).
33. de la Rosa, G. et al. Horse immunization with short-chain consensus α-neurotoxin generates antibodies against broad spectrum of elapid venomous species. Nat. Commun. 10, 1–8 (2019).
34. Abe, T., Alema, S. & Miledi, R. Isolation and characterization of presynaptically acting neurotoxins from the venom of Bungarus snakes. Eur. J. Biochem. 80, 1–12 (1977).
35. Barber, C. M., Isbister, G. K. & Hodgson, W. C. Alpha neurotoxins. Toxicon 66, 47–58, https://doi.org/10.1016/j.toxicon.2013.01.019 (2013).
36. Rowan, E. What does β-bungarotoxin do at the neuromuscular junction? Toxicon 39, 107–118 (2001).
37. Silva, A., Hodgson, W. C. & Isbister, G. Antivenom for Neuromuscular Paralysis Resulting From Snake Envenoming. Toxins 9, 143 (2017).
38. Dixon, R. W. & Harris, J. B. Nerve Terminal Damage by β-Antivenoms. Eur. J. Biochem. 100, 1–14 (1979).
39. Atassi, M. Z. Antigenic structures of proteins: their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur. J. Biochem. 199, 1–10 (1991).
40. Eisen, H. N. In Immunology: An introduction to molecular and cellular principles of the immune response. 2nd edition, Harper & Row (1980).
41. Razi Inst. of Immunobiology, A. Et al. Production of a Human Recombinant Polyclonal Fab Antivenom against Iranian Viper Echis carinatus. J. Proteom. 8, 152–156 (1997).
42. Ravi, R. & Ratanabanangkoon, K. Immunochemical and biochemical comparisons of equine monovalent and polyvalent snake antivenoms. Toxicon 45, 369–375, https://doi.org/10.1016/j.toxicon.2004.10.019 (2005).
43. Laustsen, A. H., Johansen, K. H., Engmark, M. & Andersen, M. R. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease? PLoS Negl. Trop. Dis. 11, e0003561 (2017).
44. Miersch, S. & Siddhu, S. Synthetic antibodies: concepts, potential and practical considerations. Methods 57, 486–498 (2012).
45. Laustsen, A. H. et al. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nat. Commun. 9, 1–9 (2018).
46. Motedayen, M. et al. Production of a Human Recombinant Polyclonal Fab Antivenom against Iranian Viper Echis carinatus. Arch. Razi Inst. 73, 287–294 (2018).
47. Pratanaphon, R., Akesowan, S., Khow, O., Sririprat, S. & Ratanabanangkoon, K. Production of a human Fab antivenom against the Thai cobra (Naja kaouthia). Vaccine 29, 1523–1528 (1997).
48. Williams, D. J. et al. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Negl. Trop Dis 13 (2019).
49. Karlsson, E., Arnberg, H. & Eaker, D. Isolation of the principal neurotoxins of two Naja naja subspecies. Cell Mol. Life Sci. 71, 1049–1056 (2011).
50. Williams, D. et al. Neutralization of the venom of African species of cobra by an equine antiserum against Naja melanoleuca: a comparative study. Toxicon 53, 602–608 (2009).
51. Pratanaphon, R., Akesowan, S., Khow, O., Sririprat, S. & Ratanabanangkoon, K. Production of highly potent horse antivenom against the Thai cobra (Naja kaouthia). Vaccine 28, 4465–4478, https://doi.org/10.1016/j.vaccine.2019.01.018 (2019).
52. Oh, A. M. F., Tan, C. H., Ariaranee, G. C., Quraishi, N. & Tan, N. H. Venoms of Bungarus caeruleus (Indian krait): Comparable venom profiles, variable immunoreactivities among specimens from Sri Lanka, India and Pakistan. J. Proteom. 164, 1–18, https://doi.org/10.1016/j.jprot.2017.04.018 (2017).
73. Oh, A. M. F., Tan, C. H., Tan, K. Y., Quraishi, N. H. & Tan, N. H. Venom proteome of Bungarus sindanus (Sind krait) from Pakistan and in vivo cross-neutralization of toxicity using an Indian polyvalent antivenom. *J. Proteom.* 193, 243–254 (2019).

74. Lauridsen, L. P., Laustsen, A. H., Lomonte, B. & Gutiérrez, J. M. Exploring the venom of the forest cobra snake: Toxicovencnomics and antivenom profiling of Naja melanoleuca. *J. Proteom.* 150, 98–108 (2017).

75. Tan, C. H., Wong, K. Y., Chong, H. P., Tan, N. H. & Tan, K. Y. Proteomic insights into short neurotoxin-driven, highly neurotoxic venom of Philippine cobra (Naja philippinensis) and toxicity correlation of cobra envenomation in Asia. *J. Proteomics,* 103418 (2019).

76. Tan, N. H., Wong, K. Y. & Tan, C. H. Venomics of Naja spathula, the Javan spitting cobra: A short neurotoxin-driven venom needing improved antivenom neutralization. *J. Proteom.* 157, 18–32 (2017).

77. Huang, H.-W. et al. Cobra venom proteome and glycome determined from individual snakes of Naja atra reveal medically important dynamic range and systematic geographic variation. *J. Proteom.* 128, 92–104 (2015).

78. Liu, C.-C., Lin, C.-C., Hsiao, Y.-C., Wang, P.-J. & Yu, J.-S. Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. *J. Proteom.* 187, 59–68 (2018).

79. Malih, I. et al. Proteomic analysis of Moroccan cobra Naja haje legionis venom using tandem mass spectrometry. *J. Proteom.* 96, 240–252, https://doi.org/10.1016/j.jprot.2013.11.012 (2014).

80. Hia, Y. L., Tan, K. Y. & Tan, C. H. Comparative venom proteomics of banded krait (*Bungarus fasciatus*) from five geographical locales: Correlation of venom lethality, immunoreactivity and antivenom neutralization. *Acta Tropica* 207, 105460 (2020).

Acknowledgements

This study was funded by a research grant (no. IM 2011-01 to KR) from the Chulabhorn Research Institute and a research grant from the Ministry of Higher Education, Government of Malaysia (grant no. FRGS/1/2019/SKK08/UM/02/2 to KYT and CHT). The authors are deeply grateful to Professor Arnold E. Ruoho and Dr. Nicholas V. Cozzi of University of Wisconsin, Madison; Dr. James Dubbs and Ms Sukanya Earsakul of Chulabhorn Research Institute, and Professor Jirundon Yuvaniyama of Mahidol University and Dr. Janeyuth Chaisakul for the valuable suggestions and assistance.

Author contributions

K.R., C.H.T., J.M.G. planned the experiments; K.Y.T., K.P., N.Q., C.K., conducted the experiments; K.P., K.Y.T., C.H.T., K.R. analyzed the data; K.R., C.H.T., K.Y.T., J.M.G., wrote the manuscript; all authors approved the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66657-8.

Correspondence and requests for materials should be addressed to K.R. or C.H.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020